Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,608.40
(
0.20%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
100.53
(
-0.99%
)
Bitcoin
77,856.04
(
-1.02%
)
News Focus
News Focus
Post# of 257443
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122886
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 243432

Tuesday, 11/08/2022 4:52:10 PM

Tuesday, November 08, 2022 4:52:10 PM

Post# of 257443
RVNC 3Q22 results—9/30/22 cash=$379M:

https://investors.revance.com/news-releases/news-release-details/revance-reports-third-quarter-2022-financial-results-provides

The $379M of cash at 9/30/22 does not include the second $100M tranche from the Mar 2022 loan facility, which became available to RVNC on FDA approval of Daxxify but has not yet been drawn.

3Q22 dermal-filer sales were $26.1M, +43% YoY, +2% QoQ. The small QoQ increase is consistent with seasonal patterns in the aesthetics market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today